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a  b  s  t  r  a  c  t
During  this  year’s  33rd  annual  meeting  in  Leipzig,  Germany,  the  European  Society  of  Paediatric  Infec-
tious  Diseases  (ESPID)  jointly  together  with  the European  Scientiﬁc  Working  group  on  Inﬂuenza  (ESWI),eywords:
nﬂuenza
accine
hildren
dverse events
urope
organized  a staged  debate  on  the  motion  of  universal  annual  immunization  of children  against  inﬂuenza
as  a cost-effective  health  intervention  in  Europe.  Six invited  speakers,  all experts  in the  ﬁeld  of  inﬂuenza
vaccination,  who  were  not necessary  conﬁdent  with their  given  position  of  pro  or  contra,  battled  each
other  with  short  oral  presentations  to convince  the audience  to vote  for or against  the  motion.
©  2015  The  Author.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).Opening the ﬂoor of this ESPID/ESWI Joint Symposium, the
hairman Ab Osterhaus ﬁrst of all asked the audience in the
rowded lecture hall to vote on the motion. Frankly speaking, most
articipants were either paediatricians or infectious disease spe-
ialists and supposedly because no real vaccine opponents were
resent, only few attendees voted against universal vaccination of
ll European children.
In the ﬁrst presentation, Pieter Fraaij reviewed the literature
n the incidence and outcome of inﬂuenza in different age groups.
t became clear that there is a considerable disease burden, not
nly in Europe. During annual outbreaks the number of inﬂuenza
nfections is highest in children affecting 20–30% of the total pae-
iatric population, mostly with even higher attack rates among
elected high-risk groups [1]. Children who become ill are addi-
ionally responsible for a substantial loss of parental working days.
urthermore, although most paediatric inﬂuenza cases seen in the
utpatient setting present as a self limiting respiratory disease,
very season a considerable number of children need hospital-
zation and up to 10% of all admitted children need management
n the intensive care unit (ICU) [2]. Of these ICU patients, only
alf have an underlying chronic predisposing condition (e.g. cystic
brosis, asthma, or immunodeﬁciency), while the other half repre-
ent previously healthy children progressing to severe, sometimes
ife-threatening disease with complicating conditions like ARDS,
ncephalitis, myocarditis, secondary severe bacterial infection or
ther atypical conditions.
∗ Tel.: +49 040 7410 58037; fax: +49 040 7410 59646.
E-mail address: r.kobbe@uke.de
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.018
264-410X/© 2015 The Author. Published by Elsevier Ltd. This is an open access article unAt this point a provocative thesis opened the stage for dis-
cussion: despite seasonal ﬂu being a cause of severe disease in
children, most severe cases will recover fully with oxygen, good
supportive care, speciﬁc antiviral drugs and antibiotic treatment.
To underline this argument, Fraaij cited a recent publication to
show that even after the introduction of universal inﬂuenza vac-
cination in the United States, seasonal acute respiratory infection
outbreaks will not disappear and that severe respiratory tract infec-
tions, including inﬂuenza, will always have to be managed [3].
Discussing this ﬁndings, the attentive listener asked him/herself if
this position might be untenable, simply because respiratory syn-
cytial virus, human metapneumovirus, adenovirus, and others are
different from inﬂuenza virus and not affected by inﬂuenza vacci-
nation. However, at the moment we only have an effective vaccine
against inﬂuenza available. But as Fraaij reported that only few
children die on European ICUs each year, he at the same time
raised questions like “what is a tolerable number of childhood
deaths due to inﬂuenza?”, “how these numbers carry weigh against
childhood accidents or even homicide?”, and “how shall we use
death rates and estimations on cost-effectiveness to bring forward
an argument?”. In particular paediatricians will ﬁnd it difﬁcult to
talk to parents whose child has died despite best supportive ICU
care due to a potential vaccine-preventable disease. Every doctor
and also policy maker should consider his/her child being among
the 43% of previously healthy children living in the United States
who succumbed to a disease for which we have a vaccine readily
available [4]. But during the second presentation, Terho Heikki-
nen argued that mortality is not the only reason why we should
vaccinate the children and asked the audience to look at the avail-
able data in a different way. As we are unable to predict which
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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reviously healthy individual will acquire inﬂuenza and develop a
evere form of disease, most European countries have run selective
nﬂuenza vaccination programs aiming to directly protect popula-
ions at higher risk and to thereby reduce mortality. Among these
igh risk groups are pregnant woman, the elderly, people with
hronic diseases, especially with pulmonary or heart diseases, and
mmunocompromized individuals. Studies Heikkinen et al. con-
ucted in Finland showed that every season 16.7% of all children
ell ill with laboratory conﬁrmed inﬂuenza [5]. Certainly, as in the
nited States, most cases are not life threatening and the highest
urden always lies within the community [6]. Some clinical presen-
ations are widely known, as common cold, otitis media, sinusitis
nd pneumonia, and often resolve with or without antibiotic pre-
criptions. Other severe disease phenotypes were rarely seen or
ecognized by the single general practitioner, but contributed to
ospitalization [7,8]. These studies conﬁrmed that the youngest
hildren are at highest risk, often being admitted to hospital with
 sepsis-like syndrome [9]. Heikkinen showed age-speciﬁc inci-
ence data and the need to protect infants by vaccination because
f their immature immune system, as it has never seen inﬂuenza
ntigens before, whatever strain might circulate in a given year, it is
lways a “pandemic” [10]. Before, Fraaij used the same data to argue
gainst spending money on universal childhood vaccination pro-
rams because immune responses against inﬂuenza vaccination in
nfants are poor and it had been brought forward rather to increase
fforts to vaccinate their mothers to boost maternal passive immu-
ity [11]. Of course, immunization of pregnant mothers deﬁnitely
as the potential to protect their offspring against inﬂuenza. How-
ver, maternal immunoglobulin IgG has a relatively short half-life
nd young children continue to be at risk for vaccine-preventable
iseases. Importantly, Heikkinen reported that in Finland, where
he inﬂuenza vaccine has been included in the national vaccina-
ion program for children 6–35 months of age, economical studies
ot only showed that the intervention is cost-effective, but rather
ost-saving [12]. Continuing from the economical point of view,
ichard Pebody reviewed in the following minutes several studies
hat evaluated or modelled inﬂuenza vaccination programs. Almost
ll of them reported more or less good cost-effectiveness results
13,14]. But from the political point of view, he also showed critical
ress reports on poorer inﬂuenza vaccine effectiveness than for-
erly expected. He found policy makers under pressure. Moreover,
e cited a Cochrane review that summarized to ﬁnd no evidence
f a vaccine effect on secondary cases, lower respiratory tract dis-
ase, drug prescriptions, otitis media and other consequences [15].
ebody also pointed out that in situations of limited resources in the
mmunization and public health sector budget, a choice is always
easured in terms of the value of best alternative foregone.
Adam Finn, the current president of ESPID, strongly promoted
he idea of blocking virus transmission to those at very high-risk,
ncluding pregnant women by vaccinating the children. He pre-
ented data showing that children – because of their infectiousness
 are the factories for inﬂuenza epidemics. Because they are key
layers, Finn argued, the inclusion of healthy children into national
accination programs will result in reduced mortality and over-
ll disease burden in the whole population. This indirect vaccine
fﬁcacy has been demonstrated in an elegant clinical trial of triva-
ent inactivated inﬂuenza vaccination controlled by hepatitis A
accine given to children aged 3–15 years in 50 remote isolated
utterite communities in Canada. The mass vaccination of chil-
ren in the community resulted in a 61% reduction of inﬂuenza
isease in the respective unvaccinated adult population [16]. Finn
eminded us that this study only conﬁrmed previous epidemiolog-
cal data from the United States and Japan showing that universal
accination programs indeed reduced excess deaths due to pneu-
onia and inﬂuenza in the respective populations [17]. The highly
ccepted new intranasal live attenuated inﬂuenza vaccine (LAIV),015) 6967–6969
due to safety issues only licenced in children over two  years of
age, is highly efﬁcacious with a higher protective efﬁcacy than
inactivated inﬂuenza vaccines [18]. High coverage of US school-
based LAIV programs showed an effect of indirect protection in
intervention households [19,20]. Interestingly, Finn also presented
recent implementational studies of school-based LAIV programs in
the United Kingdom and was  optimistic to achieve coverage levels
>50% that might result in an indirect effect by reducing inﬂuenza
in unvaccinated children. Unfortunately, measuring hypothetical
cost-savings of hypothetical respective positive indirect effects of
mass vaccination appears to be difﬁcult.
Finally, Miriam Sturkenboom and Timo Vesikari focused on
adverse events and side effects. In the last two  presentations they
ﬁrst described studies, reports and registry data of unwanted
pro-inﬂammatory responses and discussed the evidence of causal
relation of these with administration of inﬂuenza vaccines. ASIA,
an acronym for autoimmune/inﬂammatory syndrome induced
by adjuvants, also called Shoenfeld’s syndrome, stands for a
clinical and immunological spectrum of non-speciﬁc and speciﬁc
manifestations of autoimmune disease, mainly associated with the
adjuvants squalene and aluminium hydroxide [21]. Both adjuvants,
which were designed to enhance speciﬁc antibody production,
were accused to activate the immune system in a negative way
by releasing inﬂammatory cytokines that trigger manifestations
of autoimmunity or autoimmune disease. All licensed inactivated
inﬂuenza vaccines contain aluminium adjuvants and one contains
squalene to spare vaccine doses and induce adequate immune
response and protection in young children and the elderly. Vesikari
clearly stated that the acceptance of ASIA as a real health risk would
invalidate inﬂuenza vaccination programs as a whole, especially
if wide segments of population are being vaccinated on an annual
basis. Nevertheless, supporters of ASIA continue to relate various
forms of systemic vasculitis (e.g. leukocytoclastic vasculitis, giant
cell arteritis), SLE, rheumatoid arthritis, inﬂammatory myopa-
thy and Guillain–Barré syndrome with inﬂuenza vaccination. This
unfair, non-scientiﬁc way of undermining vaccination programs by
sprouting a theoretical risk is quite common yet causality is almost
impossible to prove, as the number of affected patients is small.
This is different for narcolepsy, a chronic debilitating sleep disor-
der caused by hypothalamic hypocretin deﬁciency. A sharp and
signiﬁcant increase in the number of newly diagnosed narcolepsy
cases among children and adolescents has been notiﬁed during the
H1N1 inﬂuenza pandemic in 2009–2010 in Finland [22]. During the
pandemic, adjuvanted vaccines were used at a large scale resulting
in a huge safety experiment at the population level. Subsequently,
an increased risk of narcolepsy only in persons under 40 years of
age vaccinated with Pandemix® was  conﬁrmed by the Swedish
registry study while there was  no signiﬁcant association with any
other disease [23]. This registry collected follow-up data of 5.8
million people (3.3 million vaccinated, 2.5 million not vaccinated)
over 2.2 years. In addition, retrospective analysis from narcolepsy
incidence data in the United Kingdom also conﬁrmed the signal
for vaccination with Pandemrix® at any time before onset of the
disease [24]. Surprisingly, narcolepsy was associated only with
the use of the AS03-adjuvanted Pandemrix® vaccine, but not seen
in association with another AS03-adjuvanted inﬂuenza vaccine
(Arepanrix®), neither in connection with a squalene only (MF59)
adjuvanted inﬂuenza vaccine nor with unadjuvanted seasonal
inﬂuenza vaccine (Fluarix®), which was produced in the same way
as Pandemrix®. Vesikari urged to take the association seriously,
as it has been suggested that the combination of squalene and
-tocopherolin was too much of a too strong adjuvant (AS03) for
an age group that did not actually need it. A recent investigation of
the production process of the “split” inﬂuenza vaccine Pandemrix
showed the formation of high quantity of the strongly immuno-
genic polymerized form of inﬂuenza nucleoprotein antigen NP,
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ot present in Arepanrix®. Especially in combination with a highly
usceptible genetic disposition (HLA-DBQ-1*602), this could have
esulted in an inherently strong response and autoimmunity,
upported by the observation that NP is recognized by antibodies
rom children with narcolepsy [25]. Vesikari suggested as one
ption for future universal vaccination programs to avoid needless
igh potent adjuvants in persons with a strong immune response,
s they could potentially trigger an autoimmune reaction.
In contrast, Miriam Sturkenboom emphasized that after the
nitial safety signal around Pandemrix® became public active
urveillance programs focused only on conditions of special inter-
st. In her presentation, she ﬁrst used the example of Guillain–Barré
yndrome (GBS) to point out that in these studies potential detec-
ion bias has not been properly addressed and that data might also
uffer from ascertainment bias [26,27]. Combining these effects
ay  well explain the observed associations, as shown by simula-
ion studies. This might be even more true when follow-up time is
hort, diagnostic lag times of these rare, formerly underdiagnosed
iseases were decreased, and ﬁnally when victim compensation
s initiated. For the case of narcolepsy, although the signalling
ountries did their best to quantify adverse events, they conducted
hese rapid risk assessment studies in the midst of the public aware-
ess. Therefore, most studies were not powered enough and media
ffects were not properly excluded so that methodically, it could
ot be distinguished between a vaccine and an awareness effect
28]. Sturkenboom summarized that in her opinion, as long as there
s no evidence-based explanation for the biological mechanisms of
andemrix® causing narcolepsy, we should not immediately dis-
ard potentially useful adjuvants.
In summary, participants of the ESPID/ESWI Joint Symposium –
ased on scientiﬁc evidence and meticulous diligence – strongly
upport universal annual immunization of all children against
nﬂuenza as a cost-effective health intervention in Europe. For
ermany, host country of this year’s ESPID annual meeting, recently
ublished epidemiological and health economic simulation data
how that national LAIV immunization of all children would lead
o a substantial reduction in inﬂuenza-associated disease at a rea-
onable cost [29,30].
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